Hansa Biopharma AB (OMX:HNSA)

European company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - HNSA

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - HNSA

  • Market CapSEK0.000m
  • SymbolOMX:HNSA
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINSE0002148817

Company Profile

Hansa Biopharma AB is a biopharmaceutical company which develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries and in the U.S.Hansa Medical AB is a biopharmaceutical company. The company, along with its subsidiaries, is engaged in the development of novel immunomodulatory enzymes. Its pipeline products include IdeS, NiceR, EndoS, and EnzE.

Latest HNSA news

Currently there for this company. Visit our news hub for other news .